Regend
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese biotech developing autologous lung progenitor cell therapies for respiratory diseases like COPD.
Respiratory
Technology Platform
Autologous lung progenitor cell technology for regenerating damaged lung tissue through ex vivo expansion and reintroduction.
Opportunities
Large global COPD market with limited disease-modifying treatments, supportive Chinese regulatory environment for cell therapies, and potential expansion to other respiratory indications.
Risk Factors
Scientific challenge of demonstrating meaningful lung tissue regeneration, clinical trial execution risks, regulatory uncertainties for novel cell therapies, and competition from both pharmaceutical and biotech approaches.
Competitive Landscape
Competes with pharmaceutical companies developing traditional respiratory drugs and other cell therapy companies; differentiation through specific focus on autologous lung progenitor cells for tissue regeneration rather than immunomodulation.